Clinical trial origAMI-2
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
| Cancers | |
|---|---|
| Organ | Colon |
| Trial status | Trial open for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Janssen Cilag |
| EudraCT Identifier | 2024-513852-13-00 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT06662786 |
| Last update |